Prevalence of the Metabolic Syndrome in SPR Taking Antipsychotics

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00569504
Recruitment Status : Unknown
Verified June 2009 by Seoul National Hospital.
Recruitment status was:  Recruiting
First Posted : December 7, 2007
Last Update Posted : June 12, 2009
Korea Otsuka Pharmaceutical Co., Ltd.
Information provided by:
Seoul National Hospital

December 6, 2007
December 7, 2007
June 12, 2009
December 2007
Not Provided
metabolic syndrome [ Time Frame: cross-sectional ]
  • Abdominal obesity [ Time Frame: cross-sectional ]
  • Triglyceride ≥ 150mg/dL [ Time Frame: cross-sectional ]
  • HDL-cholesterol < 40mg/dL(men), < 50mg/dL(female) [ Time Frame: cross-sectional ]
  • 130mmHg ≥ systolic BP, 85mmHg ≥ diastolic BP [ Time Frame: cross-sectional ]
  • FBS ≥ 100mg/dL or previous diagnosis of type II DM [ Time Frame: cross-sectional ]
Complete list of historical versions of study NCT00569504 on Archive Site
each factor of metabolic syndrome
Not Provided
Not Provided
Not Provided
Prevalence of the Metabolic Syndrome in SPR Taking Antipsychotics
Prevalence of the Metabolic Syndrome in Patients With Schizophrenia Taking Antipsychotics
The purpose of this study is to assess the cross-sectional prevalence of the metabolic syndrome in patients with schizophrenia taking antipsychotics.

Schizophrenic patients taking any kind of antipsychotics for at least 1 year at the Seoul National Hospital will be participated in this study.

we are planning to enroll approximately 1000 patients with schizophrenia.

For each subject

  • abdominal circumference
  • body mass index
  • lipid profile : TG, HDL-chlo, total chol
  • systolic/diastolic blood pressure
  • fasting blood glucose will be measured.

we will calculate the rates of patients who meet the criteria for the Metabolic syndrome.

  1. Abdominal obesity : absolute criteria
  2. 2 or more of followings

    1. Triglyceride ≥ 150mg/dL or ongoing treatment
    2. HDL-cholesterol < 40mg/dL (men) HDL-cholesterol < 50mg/dL (female) or ongoing treatment
    3. Hypertension 130mmHg ≥ systolic 85mmHg ≥ diastolic or ongoing treatment
    4. FBS ≥ 100mg/dL or previous diagnosis of type II DM
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Not Provided
Retention:   Samples Without DNA
blood sampling
Probability Sample
DSM-IV diagnosis of schizophrenia
  • Metabolic Syndrome
  • Schizophrenia
Not Provided
A, observatoin
inpatients and outpatients in Seoul National Hospital
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Unknown status
September 2009
Not Provided

Inclusion Criteria:

  • Patients taking a same antipsychotics at least more than one year
  • schizophrenia or schizoaffective disorder

Exclusion Criteria:

Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
Korea, Republic of
Not Provided
Not Provided
Shi Hyun Kang, Seoul National Hospital
Seoul National Hospital
Korea Otsuka Pharmaceutical Co., Ltd.
Study Director: Jong-il Lee, M.D. Seoul National Hospital
Seoul National Hospital
June 2009